CNBC Stock Blog
- 10 Dividend Picks For Your Portfolio: Chief Investors
- 4 Thanksgiving Week Buys For Your Portfolio: Market Pros
- There's a 'Great Chance' For a Double-Dip Recession: Strategist
- Retail Earnings and Sales to Improve in Q4: Analyst
- 4 Food Stocks to Stuff in Your Portfolio: Analyst
- S&P at 1050-1200 Trading Range Next Year: Strategist
- Art Cashin: Caution 'Growing' in Financials, Dividend Moves
- 3 Software Stock Picks from Lazard's Senior Analyst
- Investors Bet on a New Year's Rally For eBay
- Why You Should Play the Reflation Trade: Stock Picker
MOST SHARED
- Kuoni CEO Sees Recovery in Travel Sector
- Gold Retreats from Record High as Dollar Rebounds
- Dubai Struggles to Ease Debt Fears; Investors Rattled
- Chinese Overcapacity is Worsening, EU Chamber Warns
- China Unveils Carbon Target Ahead of Copenhagen
- Wal-Mart Price Pressure Hurts China Workers: Report
- Fannie Mae to Tighten Lending Standards: Report
- Great Britain, No Longer That Great: Investor
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- 4 Thanksgiving Week Buys For Your Portfolio: Market Pros
- There's a 'Great Chance' For a Double-Dip Recession: Strategist
- Revenge of the Gangsta Nerds
- Will TCU See The "Flutie Effect?"
- Retail Earnings and Sales to Improve in Q4: Analyst
- Consumers Catching the Holiday Spirit
- It's Beginning To Look A Lot More Riskless
- Crescenzi: Claims Level Suggests End to Job Losses
- Hedge Funds Take Early Lead in Warren Buffett's 'Big Bet'
- Dubai Struggles to Ease Debt Fears; Investors Rattled
- Asian Stocks Likely to Fall After Europe Selloff
- US Companies Already Moving on Curbing Emissions
- Fannie Mae to Tighten Lending Standards: Report
- Investing in Good Karma – and Making a Profit
- Retailers Should Believe in Christmas Miracles
- Bankruptcies Jump, Hitting Highest Level in Four Years
- Steepest Black Friday Discounts, Revealed
- Where Do Pardoned Turkeys Go?
RSS FEED
Text Size 
Cofounder, OptionMonster.com
Shares of Acadia Pharmaceuticals skyrocketed along with heavy options activity at the end of last week.
Acadia [
Loading...
()
] soared 31.15 percent to close Friday's regular session at $3.41 and jumped another 23.75 percent in after-hours trading. Total average volume for all options in the name is just 789 per day, but Friday saw 14,900 trades in calls alone.
The bulk of those contracts was a large spread trading 5,000 times between September 5 and 7.50 calls, according to OptionMonster's tracking systems.
The action was apparently driven by speculation over Acadia's pivotal Phase III trial of pimavanserin in patients with Parkinson's disease psychosis. Topline results from this trial are expected to be reported by the end of the third quarter, and this could be why the institiutional investor elected to play out in the September options.
The company also reports earnings results before the market opens Aug. 3 but, like most biopharmaceuticals, it's doubtful that anything but burn rate will be addressed in that release.
Acadia's options volume was 21 times average Friday, and the stock turnover was 7.7 times the normal level. Among the options, calls outnumber puts by more than 9 to 1.
___________________________
Options Trading School:
___________________________
Acadia Pharmaceuticals Competes With:
AstraZeneca [AZN
Loading...
()
]
Eli Lilly [LLY
Loading...
()
]
Pfizer [PFE
Loading...
()
]
___________________________
___________________________
Jon 'DRJ' Najarian is a professional investor, CNBC contributor, and cofounder of OptionMonster.com.
___________________________
Data is a real-time snapshot *Data is delayed at least 15 minutes